Want to find your lens? Five questions, no jargon — they tell you which of four reads fits how you already think.
We can't give an honest read on this one right now.
Our model values a company on the cash it can hand its owners after paying for its own growth. For Edwards Lifesciences that number is not something we can compute today — so rather than estimate around the gap, we are leaving it blank until the next filings close it.
Why not
- Caution: What is missingEdwards Lifesciences sold its Critical Care business to BD in September 2024. It was about a sixth of revenue, under the line where a divestiture usually breaks the base — but the free-cash-flow record does not survive it anyway: $1.4B in 2021, then $1.0B, $0.6B, $0.3B as carve-out and separation costs mounted, then $1.3B in 2025 once they cleared. Our fair value compounds from five years of free cash flow, and those five years describe a company mid-separation rather than the one that trades. 2025 is the first clean year; a five-year base that reflects it is several filings out.
Why show the page at all. Because the alternative is a number we don't believe. Every other company on TickerMath gets a fair value computed from its SEC filings; this one gets a plain explanation instead, which is the same promise kept a different way. This one is expected to change: we re-test every company against its new filings, and the read appears here as soon as the figures support it.
TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →